Evogene (EVGN) Research & Development (2012 - 2026)

Evogene has disclosed Research & Development across 15 years of filings, most recently posting $319000.0 for Q2 2026.

• In Q2 2026, Research & Development fell 9.89% year-over-year to $319000.0; the TTM figure through Jun 2026 stood at $1.4 million (down 15.23% YoY), while the FY2025 annual figure was $1.4 million, down 31.47% from the prior year.
• Research & Development came in at $319000.0 for Q2 2026 at Evogene, down from $389000.0 in the prior quarter.
• In the past five years, Research & Development ranged from a high of $1.2 million in Q4 2022 to a low of $298000.0 in Q4 2025.
• Average Research & Development over 5 years is $673555.6, with a median of $695500.0 recorded in 2023.
• The largest YoY upside for Research & Development was 62.22% in 2022 against a maximum downside of 84.64% in 2022.
• Over 5 years, Research & Development stood at $1.2 million in 2022, then slipped by 11.56% to $1.0 million in 2023, then plunged by 66.02% to $351000.0 in 2024, then slipped by 15.1% to $298000.0 in 2025, then grew by 7.05% to $319000.0 in 2026.
• Per Business Quant data, the three most recent Research & Development figures were $319000.0 in Q2 2026, $389000.0 in Q1 2026, and $298000.0 in Q4 2025.